How Medicare’s Digital Mental Health Pathway Impacts Revenue Cycle

For years, digital mental health tools sat in an awkward spot. Clinically promising, technologically ready, but financially orphaned. Digital mental health treatment (DMHT) reimbursement is Medicare’s billing pathway for FDA-cleared behavioral health devices. It is covered under three HCPCS codes, G0552, G0553, and G0554, which pay for supplying the device to a patient and for the ongoing monthly work of managing their treatment. A therapy app or FDA-cleared device could help a patient manage anxiety, insomnia, or ADHD symptoms between visits, yet there was no consistent way for a provider to bill for prescribing or managing it. That gap kept adoption slow across the US healthcare system, no matter how strong the underlying evidence looked.

That changed starting with the CY2025 Medicare Physician Fee Schedule, when CMS created three new billing codes specifically for digital mental health treatment devices ^[1]. The CY2026 update expanded that coverage further, adding FDA-cleared devices for ADHD to the list of what’s billable. For the first time, there’s an actual Medicare pathway built around this category of care.

Here’s the part that matters more for leadership: most organizations aren’t using it yet. The pathway exists, but the claims volume behind it remains low. That’s a revenue cycle and readiness problem, and it’s the kind of gap that’s worth understanding before it becomes a missed opportunity or a compliance blind spot.

The three codes CMS created are straightforward once you separate what each one actually pays for.

A few eligibility conditions apply across all three codes.

• The device has to be FDA-cleared for treating a diagnosable mental health condition.
• The billing provider has to diagnose or confirm the condition and prescribe the device as part of an active behavioral health treatment plan.
• And the device has to be used alongside ongoing behavioral health care, not as a standalone replacement for it.

That’s the pathway in concept. What it does not do, at least not yet, is set a fixed national payment rate for the device itself, which is where the next section comes in.

If this pathway has existed since 2025, the natural question is why claims volume remains low. CMS has pointed to one likely reason: the billing provider has to cover the cost of supplying the device to the patient upfront, before any reimbursement comes through.

There’s a second, less discussed reason. CMS has not set a national payment rate for the device itself under G0552. Instead, pricing is left to individual Medicare Administrative Contractors, decided contractor by contractor rather than through a single published rate^[2]. For an organization trying to figure out what a device actually pays before committing to it, that ambiguity is a real barrier.

This is the gap between a pathway existing on paper and an organization actually being able to bill against it with confidence. Right now, most are still on the wrong side of that gap.

The pricing ambiguity is exactly why organizations should get organized now, rather than wait for it to resolve on its own.

• Does your organization currently have a process for identifying which patients could be prescribed an FDA-cleared digital mental health treatment device as part of their care plan?
• Is your revenue cycle team aware that G0552, G0553, and G0554 exist, and equipped to bill them correctly once a device is in use?
• And if your Medicare Administrative Contractor has not yet published a device-specific rate, does someone on your team know how to find out, rather than assuming the pathway isn’t usable yet?

These are readiness questions. The organizations that get ahead of this now are the ones that will be positioned to bill confidently the moment pricing clarity improves.

Getting your revenue cycle ready for today’s three codes is only half the picture. The pathway itself is still moving, and two things are worth tracking beyond what’s already billable now.

First, professional groups have already asked CMS to extend this pathway further, into device categories for conditions like sleep disturbance tied to psychiatric care and fibromyalgia ^[3]. CMS didn’t accept that request for CY2026, but it left the door open for future rulemaking. That suggests the current three codes are a starting point, not the final shape of this pathway.

There is early evidence this pathway could pay off financially, not just clinically. The Peterson Health Technology Institute, an independent nonprofit that evaluates digital health technologies, assessed prescription digital therapeutics including DaylightRx and Rejoyn, the same category of FDA-cleared device covered under G0552 through G0554, and found they were associated with lower total medical claims costs, unlike blended-care programs that pair an app with live coaches or therapists, which tended to increase costs. For finance leaders weighing whether to invest in getting this billing pathway right, that is a data point worth having in the room.

Second, this isn’t a Medicare-only story. Private insurers haven’t confirmed reimbursement for these programs yet, but early digital therapeutics adopters are optimistic that Medicare’s move will build the case for commercial payers to follow^[4]. Medicare policy tends to set the pattern that commercial payers follow, so organizations planning around this pathway should think past their Medicare population alone.